Clinical Trial For Canine Lymphoma is now closed to patients

04/05/2010
Pet dogs that are enrolled in the study will receive a single dose of a novel, oral anti-cancer agent. Serial blood samples and lymph node aspirates will then be collected over a 24-hour period. Patients will return for evaluation 7 days after the single dose of therapy is administered.
For participation, clients will receive $2000 towards oncology care.

Inclusion Criteria:

-Client-owned pet dogs 1 year of age or older, 10-45kg, with life expectancy of 1 month or more;

-Informed owner consent prior to initiation of screening/treatment;

-Histological or cytological diagnosis of non-hodgkins lymphoma with one or more measurable lymph nodes (minimum tumor diameter is 20mm);

-stage II to V (only substage A) lymphoma of either B or T cell origin;

-Naive (i.e. de novo) and relapsed cases;

-Prior treatment with chemotherapy or prednisone is accepted but a 14-day washout is required.